Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular risks
Biotech
Novartis Lp(a) drug fails closely watched ph. 3 trial
Lp(a) is a known cardiovascular risk factor, but lowering it in the 8,323-patient trial didn't reduce the risk of heart attacks and strokes.
Darren Incorvaia
Sep 4, 2026 9:18pm
The 'diabolical' molecule set to become biotech's next gold rush
Apr 9, 2026 8:00am
Scribe eyes clinic as CRISPR candidates lower lipids in animals
Nov 17, 2025 9:22am
Silence says its drug lowers levels of heart disease risk factor
Feb 9, 2022 1:50pm
Lilly's tirzepatide aces 5th phase 3, teeing up filings
May 20, 2021 8:16am
Roche broadens blood test reach with sweeping new use claims
Apr 28, 2021 11:03am
